Updated 15-year follow-up data from the SWOG S0016 trial suggest chemoimmunotherapy can achieve a 42% cured fraction in patients with advanced follicular lymphoma. The long-term results also showed annual relapse risk dropping to 0.6% beyond 15 years, supporting a durable subset rather than late, persistent recurrence alone. The analysis reported a 15-year progression-free survival of 34% in the R-CHOP arm, while the CHOP plus radioimmunotherapy arm showed superior long-term progression-free outcomes in follow-up. However, overall survival benefits were not demonstrated, and the combination was associated with higher rates of myeloid neoplasms, constraining broad applicability. For clinicians and payers, the dataset re-frames follicular lymphoma’s historically incurable narrative and may influence how long-term endpoints are discussed in treatment selection, especially when weighing relapse prevention against therapy-associated risks.